Last reviewed · How we verify

N acetyl cysteine with weight reduction

Ain Shams University · Phase 3 active Small molecule

N-acetyl cysteine replenishes glutathione stores and provides antioxidant support while weight reduction interventions decrease metabolic burden and improve insulin sensitivity.

N-acetyl cysteine replenishes glutathione stores and provides antioxidant support while weight reduction interventions decrease metabolic burden and improve insulin sensitivity. Used for Metabolic syndrome with weight management, Non-alcoholic fatty liver disease (NAFLD), Insulin resistance or prediabetes.

At a glance

Generic nameN acetyl cysteine with weight reduction
SponsorAin Shams University
Drug classAntioxidant with lifestyle intervention
TargetGlutathione synthesis pathway; indirect metabolic targets via weight reduction
ModalitySmall molecule
Therapeutic areaMetabolic/Endocrinology
PhasePhase 3

Mechanism of action

N-acetyl cysteine (NAC) is a precursor to the antioxidant glutathione, which helps reduce oxidative stress and inflammation. Combined with weight reduction strategies, this approach targets metabolic dysfunction by simultaneously improving antioxidant defense and reducing adiposity-related metabolic complications. The combination may address both oxidative stress and insulin resistance in metabolic disorders.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: